# Dr. Falk Pharma GmbH clinical trials: 39 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials with Dr. Falk Pharma GmbH as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dr. Falk Pharma GmbH: 39 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/dr-falk-pharma-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 23, 2025 | NCT07298343 | Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease | Dr. Falk Pharma GmbH | Phase 2 | Recruiting | Celiac Disease | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298343) |
| March 20, 2025 | NCT06886360 | Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) | Dr. Falk Pharma GmbH | Phase 3 | Not yet recruiting | Primary Sclerosing Cholangitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06886360) |
| September 19, 2024 | NCT06596252 | Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Dr. Falk Pharma GmbH | Phase 3 | Active not recruiting | Eosinophilic Esophagitis | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06596252) |
| November 18, 2022 | NCT05621811 | Different Doses of Naronapride vs. Placebo in Gastroparesis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Gastroparesis | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05621811) |
| August 4, 2022 | NCT05488405 | Mesalazine Oral Suspension in Active Eosinophilic Esophagitis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Eosinophilic Esophagitis | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05488405) |
| March 31, 2022 | NCT05305599 | Different Doses of ZED1227 vs. Placebo in NAFLD | Dr. Falk Pharma GmbH | Phase 2 | Completed | NAFLD, Liver Fibrosis | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05305599) |
| October 19, 2021 | NCT05083390 | Norursodeoxycholic Acid vs. Placebo in NASH | Dr. Falk Pharma GmbH | Phase 2 | Unknown | Nonalcoholic Steatohepatitis | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05083390) |
| March 13, 2019 | NCT03872921 | norUrsodeoxycholic Acid vs Placebo in PSC | Dr. Falk Pharma GmbH | Phase 3 | Unknown | Primary Sclerosing Cholangitis | 303 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03872921) |
| September 15, 2015 | NCT02550418 | Budesonide 9 mg Capsules in Active UC | Dr. Falk Pharma GmbH | Phase 2 | Completed | Colitis, Ulcerative | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02550418) |
| July 9, 2015 | NCT02493335 | Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis | Dr. Falk Pharma GmbH | Phase 3 | Completed | Eosinophilic Esophagitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02493335) |
| May 5, 2015 | NCT02434029 | Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis | Dr. Falk Pharma GmbH | Phase 3 | Completed | Eosinophilic Esophagitis | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02434029) |
| October 31, 2014 | NCT02280629 | Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) | Dr. Falk Pharma GmbH | Phase 3 | Completed | Ulcerative Colitis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02280629) |
| October 31, 2014 | NCT02280616 | Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Eosinophilic Esophagitis | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02280616) |
| May 20, 2014 | NCT02142725 | Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis | Dr. Falk Pharma GmbH | Phase 3 | Terminated | Ulcerative Colitis | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02142725) |
| May 20, 2014 | NCT02142634 | Budesonide for Induction of Remission in Incomplete Microscopic Colitis | Dr. Falk Pharma GmbH | Phase 3 | Completed | Incomplete Microscopic Colitis | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02142634) |
| October 22, 2013 | NCT01966783 | Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Proctitis | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01966783) |
| May 7, 2013 | NCT01847664 | Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Uncomplicated Diverticulitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01847664) |
| December 24, 2012 | NCT01755507 | Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis | Dr. Falk Pharma GmbH | Phase 2 | Completed | Primary Sclerosing Cholangitis | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01755507) |
| December 10, 2012 | NCT01745770 | TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) | Dr. Falk Pharma GmbH | Phase 3 | Completed | Active Ulcerative Colitis | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01745770) |
| June 25, 2012 | NCT01627262 | Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study | Dr. Falk Pharma GmbH | Phase 2 | Completed | Colonic Diverticulosis | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01627262) |
| January 18, 2012 | NCT01510860 | Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis | Dr. Falk Pharma GmbH | Phase 4 | Completed | Primary Biliary Cirrhosis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01510860) |
| January 19, 2011 | NCT01279577 | Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease | Dr. Falk Pharma GmbH | Phase 2 | Completed | Crohn´s Disease | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01279577) |
| January 17, 2011 | NCT01278082 | SOIBD Collagenous Colitis Maintenance Study | Dr. Falk Pharma GmbH | Phase 3 | Completed | Induction and Maintaining Remission of Collagenous Colitis | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01278082) |
| September 27, 2010 | NCT01209208 | Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis | Dr. Falk Pharma GmbH | Phase 3 | Completed | Lymphocytic Colitis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01209208) |
| September 24, 2010 | NCT01208922 | Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea | Dr. Falk Pharma GmbH | Phase 3 | Completed | Traveler's Diarrhea | 835 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01208922) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 23 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Terminated | 5 |
| Unknown | 2 |
| Not yet recruiting | 1 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colitis, Ulcerative | 6 |
| Eosinophilic Esophagitis | 5 |
| Crohn Disease | 4 |
| Cholangitis, Sclerosing | 3 |
| Diverticulitis | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Liver Cirrhosis, Biliary | 2 |
| Colitis, Collagenous | 2 |
| Esophageal Diseases | 1 |
| Esophagitis | 1 |
| Gastroparesis | 1 |
| Diabetes Mellitus | 1 |
| Diverticulosis, Colonic | 1 |
| Diverticular Diseases | 1 |
| Colitis, Lymphocytic | 1 |
| Proctitis | 1 |
| Recurrence | 1 |
| Celiac Disease | 1 |
| Liver Cirrhosis | 1 |
| Hepatitis, Autoimmune | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Transcription services in the United States](https://specstream.ai/data/businesses/transcription-services/united-states)
- [Dominican restaurants in the United States](https://specstream.ai/data/businesses/dominican-restaurants/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Rail services in the United States](https://specstream.ai/data/businesses/rail-services/united-states)
